New hope for older AML patients: study tests smarter drug combos to beat relapse
NCT ID NCT06532552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares four different drug combinations for adults newly diagnosed with acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy or choose not to have it. The goal is to see which combination works best to keep the cancer away longer and with fewer side effects. About 172 participants will be randomly assigned to one of four treatment groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill boost standard therapy for hard-to-treat leukemia?
- Engineered immune cells take aim at Hard-to-Treat leukemia
- New drug cocktail aims to beat back stubborn leukemia
- New pill combo aims to tackle tough leukemia
- Could a liver-protecting herb boost leukemia chemo? new trial aims to find out.
- New triple therapy aims to boost survival in frail AML patients